THE OBESITY SOCIETY

Professionals Collaborating to Overcome Obesity

Assessing and Treating Older Adults with Obesity Course at ObesityWeek® 2025

Credit for this course may not exceed 6.75 credits when both the live and enduring material activity format credits are combined.

Live Course Accreditation and Credit for Physicians

The Obesity Society is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
The Obesity Society designates this live activity for a maximum of **6.75** *AMA PRA Category 1 Credits*™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to **6.75** MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

ACCME Activity ID 203331125

On-Demand Course Accreditation and Credit for Physicians

The Obesity Society is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The Obesity Society designates this enduring material for a maximum of **6.75** *AMA PRA Category 1 Credits*™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to **6.75** MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

ACCME Activity ID 203331133

Important Dates for On-Demand Course (Enduring Material)

Date of Release: January 2, 2026
Date of Termination: December 31, 2028

Learning Objectives

1. Use a personalized approach in conducting a complete assessment of older adults for clinical concerns related to body size and the older adults' concerns about activities of daily living and "what matters to them."

2. Assess the impact of weight loss on muscle and bones.

3. Apply accepted national guidelines in the evaluation and treatment of older adults with overweight and obesity.

4. Formulate an interprofessional plan of care for older adults with obesity aligned with their goals of care, including their goals around quality of life and function.

Commercial Support

No commercial support was received for this activity.

Faculty and Planning Committee Disclosure Information

The Obesity Society adheres to the ACCME's Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CE activity - including faculty, planners, reviewers or others - are required to disclose all financial relationships with ineligible entities[1] (commercial interests). All relevant financial relationships have been mitigated prior to the commencement of the activity.

The Obesity Society asks all individuals involved in the development and presentation of Continuing Medical Education (CME) activities to disclose all financial relationships with ineligible companies. This information is disclosed to CME activity participants. The Obesity Society has procedures to mitigate financial relationships. In addition, faculty members are asked to disclose when any unapproved use of pharmaceuticals or devices is being discussed.

[1] An ineligible company as defined by the ACCME is one that is not eligible for ACCME accreditation, in other words those whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. Examples of such organizations include: 1) Advertising, marketing, or communication firms whose clients are ineligible companies, 2) Bio-medical startups that have begun a governmental regulatory approval process, 3) Compounding pharmacies that manufacture proprietary compound, 4) Device manufacturers or distributors, 5) Diagnostic labs that sell proprietary products, 6) Growers, distributors, manufacturers or sellers of medical foods and dietary supplements, 7) Manufacturers of health-related wearable products, 8) Pharmaceutical companies or distributors, 9) Pharmacy benefit managers, 10) Reagent manufacturers or sellers. Reference: https://accme.org/faq/what-accmes-definition-ineligible-company

Chairs:

At TOS activities, course/session chairs are responsible for timekeeping, introductions, housekeeping announcements, and presenting audience questions to speakers. TOS has determined that chairs do not have the ability to influence content. Accordingly, TOS does not collect, mitigate, or disclose relevant financial relationships of chairs (unless they have a dual role as a planner or speaker).

Panelists:

Panelists are speakers who speak without presenting slides in a portion of a session or course. As speakers, they are required to disclose, and their relevant financial relationships are listed below. All speakers - with or without relevant financial relationships, with or without slides - are advised, and subsequently attest that "The content and/or presentation of the information with which I am involved will promote quality or improvements in health care and will not promote a specific proprietary business interest or a commercial interest (including ACCME-defined ineligible companies). Content for this activity, including any presentation of therapeutic options, will be balanced, evidence-based and commercially unbiased."

Speaker Disclosures:

Luca Busetto, MD, PhD	• Advisor relationship with Eli Lilly, Novo Nordisk, and Regeneron (Pharmaceuticals).
Kristen Beavers, PhD, MPH, RD	• Advisor relationship with Haleon (Medical Supplement) and Novo Nordisk (Pharmaceuticals). • Researcher relationship with Jason (Pharmaceuticals).
Tiffany Cortes, MD	• Researcher relationship with CJ-Cheil-Jedang-Corporation (Medical Supplement).
Denise Houston, PhD, RD	• No Relevant Financial Relationships
Jennifer Pettis, RN, MS, CNE	• Grant Funding Support relationship with Novo Nordisk (Pharmaceuticals).
Carla Prado, PhD, RD	• Consultant relationship with Nutricia (Medical Food). • Speaker relationship with Abbott Nutrition and Nestle Health Sciences (Medical Food), and Novo Nordisk (Pharmaceuticals).
Volkan Yumuk, MD	• Advisor relationship with Eli Lilly, Novo Nordisk, and Regeneron (Pharmaceuticals). • Speaker relationship with Rhythm (Pharmaceuticals).

Planner Disclosures:

John Batsis, MD, FACP, FTOS, AGSF, FGSA	• Consultant relationship with Regeneron (Pharmaceuticals).
Jennifer Pettis, RN, MS, CNE	• Grant Funding Support relationship with Novo Nordisk (Pharmaceuticals).
Kathryn Porter-Starr, PhD, RDN, LDN	• No Relevant Financial Relationships

Reviewer Disclosures: No members of the TOS CME Oversight Committee, charged with the resolution of all relevant conflicts of interest, had any relevant financial relationships while serving on the committee.

Bibliography

1. The Gerontological Society of America KAER Toolkit for the Management of Obesity in Older Adults. Gerontological Society of America;2022. www.geron.org/obesity

2. Batsis JA, Zagaria AB. Addressing obesity in aging patients. Med Clin North Am. 2018;102(1):65–85. doi:10.1016/j.mcna.2017.08.007

3. Porter Starr KN, McDonald SR, Weidner JA, Bales CW. Challenges in the management of geriatric obesity in high-risk populations. Nutrients. 2016;8(5):262. doi:10.3390/nu8050262

4. Jensen et al., 2013 AHA/ACC/TOS Guideline for the management of overweight and obesity in adults: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and The Obesity Society, Journal of the American College of Cardiology. 2014; 63(25):2985–3023.

5. Garvey, W. T., Mechanick, J. I., Brett, E. M., Garber, A. J., Hurley, D. L., Jastreboff, A. M., Nadolsky, K., Pessah-Pollack, R., Plodkowski, R., & Reviewers of the AACE/ACE Obesity Clinical Practice Guidelines (2016). American Association of Clinical Endocrinologists and American College of Endocrinology Comprehensive Clinical Practice Guidelines for Medical Care of Patients with Obesity. *Endocrine Practice : Official Journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists*, *22 Suppl 3*, 1–203. https://doi.org/10.4158/EP161365.GL

Disclaimer

These materials and all other materials provided in conjunction with continuing medical education activities are intended solely for the purposes of supplementing continuing medical education programs for qualified health care professionals. Anyone using the materials assumes full responsibility and all risk for their appropriate use. The Obesity Society makes no warranties or representations whatsoever regarding the accuracy, completeness, currentness, noninfringement, merchantability or fitness for a particular purpose of the materials. In no event will The Obesity Society be liable to anyone for any decision made or action taken in reliance on the materials. In no event should the information in the materials be used as a substitute for professional care.

This document was last updated October 28, 2025.